Fully human Fab synthetic library

Fully human Fab synthetic library

Constream Biotech currently has a library capacity of 10 11 of a fully human Fab synthetic library. The ultimate goal is to establish a 100-billion-level fully human Fab synthetic library, dedicated to developing high-affinity, high-specificity candidate antibodies for pharmaceutical companies and diagnostic reagent companies.


Constream Biotech currently has a library capacity of 10 11 of a fully human Fab synthetic library. The ultimate goal is to establish a 100-billion-level fully human Fab synthetic library, dedicated to developing high-affinity, high-specificity candidate antibodies for pharmaceutical companies and diagnostic reagent companies.

Service Advantages

● Optimal germline sequences: suitable for phage display, high expression, and good druggability

● Randomization strategy: Trimer primers, diverse CDR3 lengths, and diverse amino acid distribution

● Optimal library capacity: Library capacity close to 10 11 Good diversity, reduced ineffective screening

● Widest application: Verified by dozens of targets, suitable for different types of targets, affinity reaching pM

Service Content

Serial Number

Main Steps

Content

Cycle

Delivery Results

1

Antigen Preparation

Customer provides 2mg antigen for screening and preliminary identification

 

 

2

Phage Library Screening (Fully Human Fab Synthetic Library)

1. 3-4 rounds of panning 
2. Candidate clone identification

3. ELISA ranking 
4. Sequencing and sequence analysis

4-8 weeks

Up to 40 sequences will be provided in batches (20 in the first batch, 20 in the second batch) for full antibody expression and activity verification by the customer.

3

Full Antibody Expression and Purification

The antibodies obtained from phage screening will be converted into full antibody forms (IgG1 or customer-specified full antibody forms) for expression and affinity purification.

2-3 weeks

Up to 1mg protein per sequence (concentration >1mg/ml, 1-step purification: SEC >95%, SDS-PAGE >95%)

4

Total Cycle

6-11 weeks

Service Cases

Synthetic Phage Library Display Technology Screening Cases

Name

Commercial Name

Format

Target

Company

Clinical Indication

Status

Phage Display Type

Atezolizumab

Tecentriq

Humanized IgG1

PD-L1

Roche, 
Genentech

Cancers, 
Melanoma, 
Solid Tumors, hepatocellular carcinoma, 
others

Market

Human Library 
(Fab`-zip synthetic single-framework)

Brodalumab

Kyntheum, 
Siliq

Human IgG2

IL-17RA

Valeant Pharmaceuticals; LEO Pharma

Plaque psoriasis

Market

MorphoSyś HuCAL

Faricimab

Vabysmo

Human/Humanized IgG1

VEGF-A, Ang-2

Roche

Macular degeneration

Approved

Synthetic human Fab library

Guselkumab

TREMFYA™

Human IgG1

IL23A

Morphosys (Germany); Morphosys and Janssen Biotech (USA)

Psoriatic arthritis, psoriasis, palmoplantar pustulosis, others

Approved

MorphoSyś HuCAL

Tafasitamab

Monjuvi

Humanized IgG1/2

CD19

Xencor

Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia

Approved

MorphoSyś HuCAL

Tebentafusp

KIMMTRAK

Human TCR-scFv

gp100, CD3

Immunocore

Metastatic uveal melanoma

Approved

Synthetic TCR-phage library

Tralokinumab

Adbry™ (USA) 
Adtralza® (EU)

Human IgG4

IL-13

LEO Pharma

Atopic dermatitis, 
asthma

Approved

Synthetic human scFv library

Felzartamab

N/A

IgG1-lambda

CD38

HI-Bio

MM

Phase II-III

Synthetic Fab HuCAL GOLD (MorphoSyś)

Anetumab 
ravtansine

N/A

Human IgG1-lambda – DM4

MSLN

Bayer

Solid tumors, MPM

Phase II

MorphoSyś HuCAL GOLD

Carlumab

N/A

Human IgG1-kappa

CCL2

Gilead Sciences

PCa

Phase I-II

MorphoSyś HuCAL GOLD

Documents